A screen against leishmania intracellular amastigotes: Comparison to a promastigote screen and identification of a host cell-specific hit

PLoS Neglected Tropical Diseases

Volumn 5, Issue 7, 2011, Pages

  De Muylder, Geraldine ^a   Ang, Kenny K H ^b   Chen, Steven ^b   Arkin, Michelle R ^b   Engel, Juan C ^a   McKerrow, James H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONAZINE; NALOXONE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE;

AMASTIGOTE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LEISHMANIA; LEISHMANIA DONOVANI; NONHUMAN; PROMASTIGOTE; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HOST PARASITE INTERACTION; LEISHMANIASIS; LIFE CYCLE STAGE; MACROPHAGE; MOLECULAR LIBRARY; PARASITOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE, TUMOR; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HOST-PARASITE INTERACTIONS; HUMANS; LEISHMANIA; LEISHMANIASIS; LIFE CYCLE STAGES; MACROPHAGES; NALOXONE; SMALL MOLECULE LIBRARIES;

EID: 79960945898     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001253     Document Type: Article

References (46)

1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
2. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
3. Handman E, Bullen DV, (2002) Interaction of Leishmania with the host macrophage. Trends Parasitol 18: 332-334.
4. Croft SL, Seifert K, Yardley V, (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123: 399-410.
5. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, et al. (2009) Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599-614.
6. Singh S, Sivakumar R, (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 10: 307-315.
7. Davis AJ, Kedzierski L, (2005) Recent advances in antileishmanial drug development. Curr Opin Investig Drugs 6: 163-169.
8. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, Croft SL, Sundar S, et al. (2006) Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat 9: 26-39.
9. Renslo AR, McKerrow JH, (2006) Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2: 701-710.
10. Nwaka S, Hudson A, (2006) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
11. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, et al. (2010) Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis 4: e675.
12. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, et al. (2009) Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3: e540.
13. St George S, Bishop JV, Titus RG, Selitrennikoff CP, (2006) Novel compounds active against Leishmania major. Antimicrob Agents Chemother 50: 474-479.
14. Fumarola L, Spinelli R, Brandonisio O, (2004) In vitro assays for evaluation of drug activity against Leishmania spp. Res Microbiol 155: 224-230.
15. Doyle PS, Engel JC, Pimenta PF, da Silva PP, Dwyer DM, (1991) Leishmania donovani: long-term culture of axenic amastigotes at 37 degrees C. Exp Parasitol 73: 326-334.
16. Bates PA, Robertson CD, Tetley L, Coombs GH, (1992) Axenic cultivation and characterization of Leishmania mexicana amastigote-like forms. Parasitology 105 (Pt 2): 193-202.
17. Callahan HL, Portal AC, Devereaux R, Grogl M, (1997) An axenic amastigote system for drug screening. Antimicrob Agents Chemother 41: 818-822.
18. Rochette A, Raymond F, Corbeil J, Ouellette M, Papadopoulou B, (2009) Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum. Mol Biochem Parasitol 165: 32-47.
19. Buckner FS, Wilson AJ, (2005) Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am J Trop Med Hyg 72: 600-605.
20. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, et al. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53: 3855-3859.
21. Engel JC, Parodi AJ, (1985) Trypanosoma cruzi cells undergo an alteration in protein N-glycosylation upon differentiation. J Biol Chem 260: 10105-10110.
22. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, et al. (2003) An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol 130: 31-42.
23. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
24. Gebre-Hiwot A, Tadesse G, Croft SL, Frommel D, (1992) An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop 51: 237-245.
25. Ogunkolade BW, Colomb-Valet I, Monjour L, Rhodes-Feuillette A, Abita JP, et al. (1990) Interactions between the human monocytic leukaemia THP-1 cell line and Old and New World species of Leishmania. Acta Trop 47: 171-176.
26. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, et al. (2006) Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 67: 355-363.
27. Kangas L, Gronroos M, Nieminen AL, (1984) Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 62: 338-343.
28. Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A, (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 56: 3-7.
29. Neal RA, Croft SL, (1984) An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother 14: 463-475.
30. Dube A, Gupta R, Singh N, (2009) Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 25: 432-439.
31. Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, et al. (2010) Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob Agents Chemother 54: 3326-3334.
32. El-Sayed NM, Myler PJ, Bartholomeu DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309: 409-415.
33. Locher CP, Ruben PC, Gut J, Rosenthal PJ, (2003) 5HT1A serotonin receptor agonists inhibit Plasmodium falciparum by blocking a membrane channel. Antimicrob Agents Chemother 47: 3806-3809.
34. Jones DC, Hallyburton I, Stojanovski L, Read KD, Frearson JA, et al. (2010) Identification of a kappa-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol 80: 1478-1486.
35. Singal P, Kinhikar AG, Singh S, Singh PP, (2002) Neuroimmunomodulatory effects of morphine in Leishmania donovani-infected hamsters. Neuroimmunomodulation 10: 261-269.
36. Rahman MA, Azuma Y, Fukunaga H, Murakami T, Sugi K, et al. (2005) Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia. J Antimicrob Chemother 56: 861-868.
37. Gets J, Monroy FP, (2005) Effects of alpha- and beta-adrenergic agonists on Toxoplasma gondii infection in murine macrophages. J Parasitol 91: 193-195.
38. Schwegmann A, Brombacher F, (2008) Host-directed drug targeting of factors hijacked by pathogens. Sci Signal 1: re8.
39. Jayaswal S, Kamal MA, Dua R, Gupta S, Majumdar T, et al. (2010) Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog 6: e1000839.
40. Hahn EF, Pasternak GW, (1982) Naloxonazine, a potent, long-lasting inhibitor of opiate binding sites. Life Sci 31: 1385-1388.
41. Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, et al. (2006) Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol 1: 260-269.
42. Sharp BM, Roy S, Bidlack JM, (1998) Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol 83: 45-56.
43. Roy S, Wang J, Kelschenbach J, Koodie L, Martin J, (2006) Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol 1: 77-89.
44. Pacifici R, Minetti M, Zuccaro P, Pietraforte D, (1995) Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide release. Int J Immunopharmacol 17: 771-777.
45. Singh PP, Singal P, (2007) Morphine-induced neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines and nitric oxide. J Neuroimmune Pharmacol 2: 338-351.
46. Ling GS, Simantov R, Clark JA, Pasternak GW, (1986) Naloxonazine actions in vivo. Eur J Pharmacol 129: 33-38.